One interpretation of these data is that neither bevacizumab nor sunitinib is effective at targeting prostate cancer cells with stem cell properties and that the CSC population, which is characterized by autocrine VEGF/NRP signaling, is enriched by treatment with these drugs because they target primarily non-CSCs. The gene discussed is NRP1; the disease is prostate cancer.